Sign in
CompletedPhase 2

Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously

Key facts

Who runs it
Pharmicell Co., Ltd.
Where
South Korea4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
54 people enrolled
Started
19 Oct 2020
Ended
7 Jan 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Cellgram-ED
Record updated
9 February 2026

Who can take part

Age
19 years to 79 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Men aged 19 to 80 years old at screening
  • Patients who maintained normal foot function before prostatectomy and are interested in restoring sexual function after surgery
  • PSA level <10 ng/mL before prostatectomy
  • Pathological Gleason sum ≤ 7(3+4 or 4+3) factor during prostatectomy
  • Local lesions that did not metastasize during prostatectomy (pT2, N0, M0 stage) factors
  • Patients more than 1 year after prostatectomy and PSA ≤ 0.04 ng/mL when screened without additional treatment other than surgery
  • Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks
  • Total score of 10 or more and 17 or less in the EF (Erectile function) field* of the International Erectile Function Questionnaire; 1, 2, 3, 4, 5, 15 questions for EF erectile function in the international erectile function questionnaire
  • Prevalence for erectile dysfunction at screening with more than 6 months
  • Who are willing to engage in sexual activity more than 4 times a month and have a constant partner for at least 3 months
  • Who do not have difficulty reading and understanding the contents of the questionnaire and who fill out a complete questionnaire
  • A person who voluntarily agrees to participate in this clinical trial and has signed the consent form by the subject and the subject partner

Who cannot take part

  • Those with the following medical history/companion diseases A. Gentamicin hypersensitivity reaction B. Solid cancer or malignant blood disease within 5 years prior to screening C. Clinically significant cognitive impairment, dementia or psychiatric disorder D. Alcohol or substance abuse E. Priapism F. Severe respiratory diseases (COPD, asthma, pneumonia, pulmonary embolism, pneumothorax, etc.) G. Stroke H. Systemic autoimmune disease
  • Those who possess the following therapeutic powers at screening A. Who are being treated for severe systemic or local infection B. Long-term use of anticoagulant (warfarin) (administered for more than 3 months as anticoagulant therapy) C. Vacuum compressor or intracavernous injection therapy within 7 days before screening (prostaglandin E1, papaverine, phentolamine, etc.) D. Immunosuppressants, alpha blockers or male hormones (androgens, anti-androgens) within 28 days prior to screening
  • Who are receiving drugs* that are expected to affect the results of this clinical trial when judged by the investigator
  • Who participated in other interventional clinical trials within 4 weeks prior to the screening visit and received clinical investigational drugs/investigational medical devices or received procedures
  • Who have or will be administered other cell therapy products
  • Severe cardiovascular disease (angina pectoris, myocardial infarction, unstable arrhythmia, heart failure, etc.) at the screening visit
  • Who cannot collect bone marrow due to bone marrow disease, etc
  • Penile anatomical malformations (ex: Peyronie's disease) or penile implants or penile vascular procedures
  • Who attempts sexual activity more than 4 times during the run-in period and has a failure rate (Sexual Encounter Profile) of 50% or more
  • Those with the following test results at the screening visit A. Liver disease or abnormal liver function (AST or ALT ≥ 3 times the normal upper limit of the organ) B. Severe renal impairment (serum creatinine≥ 2 mg/dL) C. Positive factors for pathogenic microbial tests (Hbs Ag, HCV Ab, HIV Ab, Syphilis) D. Uncontrolled high blood pressure (systolic blood pressure >170 mmHg or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg, diastolic blood pressure <50 mmHg) E. Who are outside the normal range of tumor marker tests (PSA, CEA, AFP) F. Hemorrhagic tendency (PT and aPTT> ULN x 1.5) G. Untreated hypogonadism or serum testosterone hormone less than 200 ng/dL
  • If the partner is a woman of childbearing potential, those who are not willing to use an appropriate contraceptive method** during the clinical trial period; **Contraceptive administration and implantation or intrauterine device, infertility procedures (vapectomy, tubal ligation, etc.), blocking method (condom, contraceptive diaphragm, vaginal sponge or cervical cap)
  • A person who is judged to be inappropriate to participate in this test when judged by the examiner; Random Inclusion Criteria:
  • Total score of 10 or more and 17 or less in the EF (Erectile function) field* of the International Erectile Function Questionnaire (IIEF); 1, 2, 3, 4, 5, 15 questions for EF erectile function in the international erectile function questionnaire

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This phase II clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

The 2 groups in the trial

  • Placebo-Control groupNo study treatment, for comparison

    Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.

  • Injection group: Cellgram-EDTreatment being tested

    Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.

    Treatment: Cellgram-ED

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Single-blind, Multi-center, Randomization, Phase Ⅱ Study to Evaluate Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-derived Mesenchymal Stem Cells) in Erectile Dysfunction Patients With Following Radical Prostatectomy
Record updated
9 February 2026